Syngenta biologicals grow double digits as European drought cuts crop protection sales
Syngenta Group Q3 2026 sales fell 10% to $5.2bn as European drought cut crop protection demand, while biologicals grew double digits.
Syngenta Group reported its nine-month 2026 results on 30 October 2026. Group sales fell 5 per cent to 17.3 billion dollars from 18.2 billion a year earlier, a decline of 8 per cent at constant exchange rates. Third quarter sales dropped 10 per cent to 5.2 billion dollars from 5.7 billion, down 12 per cent at constant currency. Nine-month EBITDA rose 1 per cent to 3.2 billion dollars.
Profitability moved the other way from the top line. The nine-month EBITDA margin reached 18.4 per cent, up 100 basis points from 17.4 per cent, and underlying sales rose 1 per cent once planned reductions in grain trading and other low-margin business are stripped out. Third quarter EBITDA slipped 2 per cent to 0.8 billion dollars, or 4 per cent at constant rates.
The group put the demand shortfall down to the weather. It cited "the persistent drought in Europe where unusually hot and dry conditions prevailed", which limited crop development and the window for applications and therefore the need for crop protection products. Pressure on farm incomes made growers more cautious about buying seed and chemistry, and purchasing decisions slipped in several markets. Syngenta Crop Protection still booked nine-month sales of 9.8 billion dollars, flat year on year and down 4 per cent at constant currency, with Europe up 6 per cent mostly on currency effects, China up 20 per cent, Brazil down 6 per cent and Latin America down 14 per cent.
Against that backdrop biologicals delivered double-digit growth in the third quarter, driven by Brazil and China, and the group announced three new biologicals innovations in September 2026. TYMIRIUM, which targets nematodes and fungal diseases at very low application rates, continued its global rollout with strong sales in Brazil, China and the United States, while the broad-spectrum insecticide PLINAZOLIN expanded further across Asia, the Middle East, Africa and Latin America. Syngenta Seeds held nine-month sales at 3.3 billion dollars and ADAMA at 3.0 billion, while Syngenta Group China fell 18 per cent to 3.1 billion on deliberate cuts to low-margin volume. This is a separate development from the group's listing preparations covered here on 28 October. Gaël Hili took over as President of Syngenta Seeds on 1 November 2026, moving across from President and chief executive of ADAMA, where Dr Zhigang Hao, until now chief executive of Adisseo, succeeds him.
Why it matters for AgTech founders: this is the clearest read so far on how a drought year travels through the input channel. When the application window closes, chemistry revenue does not slide into the next quarter, it disappears, and the distributor between you and the grower absorbs the shock first by simply not reordering. Two numbers here belong in your next board pack. First, the biologicals line grew double digits in the same quarter chemistry fell, and it grew in Brazil and China rather than Europe, which says where budget for new modes of action actually sits right now. Second, the group widened margin by 100 basis points while shrinking revenue on purpose, which is how a buyer behaves when it is tightening its portfolio. If you are selling into one of these businesses, prepare for a harder question about gross margin contribution than about agronomic novelty, and assume European pilots will be the slowest to convert this season.
Syngenta biologicals grow double digits as European drought cuts crop protection sales
Group third quarter sales fell 10 per cent to 5.2 billion dollars after a hot, dry European season, yet the nine-month margin widened by 100 basis points and the biologicals line kept growing.
Syngenta Group reported its nine-month 2026 results on 30 October 2026. Group sales fell 5 per cent to 17.3 billion dollars from 18.2 billion a year earlier, a decline of 8 per cent at constant exchange rates. Third quarter sales dropped 10 per cent to 5.2 billion dollars from 5.7 billion, down 12 per cent at constant currency. Nine-month EBITDA rose 1 per cent to 3.2 billion dollars.
Profitability moved the other way from the top line. The nine-month EBITDA margin reached 18.4 per cent, up 100 basis points from 17.4 per cent, and underlying sales rose 1 per cent once planned reductions in grain trading and other low-margin business are stripped out. Third quarter EBITDA slipped 2 per cent to 0.8 billion dollars, or 4 per cent at constant rates.
The group put the demand shortfall down to the weather. It cited "the persistent drought in Europe where unusually hot and dry conditions prevailed", which limited crop development and the window for applications and therefore the need for crop protection products. Pressure on farm incomes made growers more cautious about buying seed and chemistry, and purchasing decisions slipped in several markets. Syngenta Crop Protection still booked nine-month sales of 9.8 billion dollars, flat year on year and down 4 per cent at constant currency, with Europe up 6 per cent mostly on currency effects, China up 20 per cent, Brazil down 6 per cent and Latin America down 14 per cent.
Against that backdrop biologicals delivered double-digit growth in the third quarter, driven by Brazil and China, and the group announced three new biologicals innovations in September 2026. TYMIRIUM, which targets nematodes and fungal diseases at very low application rates, continued its global rollout with strong sales in Brazil, China and the United States, while the broad-spectrum insecticide PLINAZOLIN expanded further across Asia, the Middle East, Africa and Latin America. Syngenta Seeds held nine-month sales at 3.3 billion dollars and ADAMA at 3.0 billion, while Syngenta Group China fell 18 per cent to 3.1 billion on deliberate cuts to low-margin volume. This is a separate development from the group's listing preparations covered here on 28 October. Gaël Hili took over as President of Syngenta Seeds on 1 November 2026, moving across from President and chief executive of ADAMA, where Dr Zhigang Hao, until now chief executive of Adisseo, succeeds him.
Why it matters for AgTech founders: this is the clearest read so far on how a drought year travels through the input channel. When the application window closes, chemistry revenue does not slide into the next quarter, it disappears, and the distributor between you and the grower absorbs the shock first by simply not reordering. Two numbers here belong in your next board pack. First, the biologicals line grew double digits in the same quarter chemistry fell, and it grew in Brazil and China rather than Europe, which says where budget for new modes of action actually sits right now. Second, the group widened margin by 100 basis points while shrinking revenue on purpose, which is how a buyer behaves when it is tightening its portfolio. If you are selling into one of these businesses, prepare for a harder question about gross margin contribution than about agronomic novelty, and assume European pilots will be the slowest to convert this season.